CVA Family Office’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
CVA Family Office's VRTX Position: Q2 2026 in Review
CVA Family Office increased its Vertex Pharmaceuticals (VRTX) stake by 2.1% in Q2 2026, buying an estimated $4.43K and bringing the position to 482 shares worth $239K. The position accounts for 0.02% of the portfolio, ranked #310.
CVA Family Office first reported a position in VRTX in Q1 2021 and has held it in 20 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- CVA Family Office held 482 shares of Vertex Pharmaceuticals worth $239K as of Q2 2026.
- CVA Family Office bought 10 Vertex Pharmaceuticals shares in Q2 2026, an estimated $4.43K.
- Vertex Pharmaceuticals made up 0.02% of CVA Family Office's portfolio in Q2 2026, its #310 holding.
- CVA Family Office first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 20 quarters since.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.